Core Viewpoint - The stock of Jianghai Medical Technology (02225.HK) has seen a significant increase, rising over 13% and currently trading at 1.29 HKD with a trading volume of 13.0365 million HKD [2] Company Summary - Jianghai Medical Technology's stock price increased by 5.74% at the time of reporting [2] - The total trading volume reached 13.0365 million HKD, indicating active market participation [2]

Core Viewpoint - Jin Hai Medical Technology (02225) has seen a significant stock increase of over 13%, currently trading at 1.29 HKD with a transaction volume of 13.0365 million HKD, following the announcement of a strategic cooperation framework agreement with Medtronic for the promotion of real-time navigation tracking endoscopic spine technology in China [1] Group 1: Strategic Cooperation - Jin Hai Medical Technology's subsidiary, Jin Hai Shanghai, has entered into a strategic cooperation framework agreement with Medtronic Changzhou to develop a leading domestic and internationally advanced integrated solution for navigation endoscopic spine technology [1] - The agreement aims to address clinical needs and will involve resource investment for domestic and international academic exchange activities to promote the clinical academic exchange and technological advancement of real-time navigation tracking endoscopic spine technology in China [1] - Both parties will provide navigation endoscopic spine prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the technology [1] Group 2: Upcoming Events - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, during which Jin Hai Medical Technology will jointly launch the latest developed navigation endoscopic spine innovation technology with Medtronic China [1] - This new technology is expected to be applicable in spinal surgery, paving the way for precision and intelligent development in spinal procedures, while also shortening the learning curve for clinicians in endoscopic spine technology [1] - The initiative is anticipated to facilitate more efficient and widespread clinical applications in the future [1]

Core Viewpoint - Jinhai Medical Technology (02225) has seen a significant stock increase of over 13%, currently trading at 1.29 HKD, with a transaction volume of 13.0365 million HKD, following the announcement of a strategic cooperation framework agreement with Medtronic for the promotion of real-time navigation tracking endoscopic spine technology in China [1] Group 1: Strategic Cooperation - Jinhai Medical Technology's subsidiary, Jinhai Shanghai, has entered into a strategic cooperation framework agreement with Medtronic Changzhou to develop a leading domestic and internationally advanced integrated solution for navigation endoscopic spine technology [1] - The partnership aims to address clinical needs, organize domestic and international academic exchange activities, and promote the clinical academic exchange and technological advancement of real-time navigation tracking endoscopic spine technology in China [1] - Both parties will provide navigation endoscopic spine prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the technology [1] Group 2: Upcoming Events - The 8th China International Import Expo (CIIE) will be held in Shanghai from November 5 to 10, during which Jinhai Medical Technology will jointly launch the latest developed navigation endoscopic spine innovation technology with Medtronic China [1] - This new technology is expected to be applicable in spinal surgery, paving the way for precision and intelligent development in spinal procedures, while also shortening the learning curve for clinicians in endoscopic spine technology [1] - The initiative is anticipated to facilitate more efficient and widespread clinical applications in the future [1]

Company News - BeiGene reported total revenue of approximately $3.845 billion for the first nine months, a year-on-year increase of 43%. Adjusted net profit was approximately $693 million, marking a return to profitability. In Q3, revenue reached $1.412 billion, up 41% year-on-year, with adjusted net profit of approximately $304 million, a 489% increase year-on-year. The growth is primarily attributed to the sales increase of BeiYueZe® in the US and Europe, with the US remaining the largest market for the company. The full-year revenue guidance is set at $5.1 billion to $5.3 billion, reflecting strong growth expectations from BeiYueZe® in the US and continued expansion in Europe and other key global markets [2] - Yidu International Holdings announced an earnings upgrade, expecting a profit attributable to shareholders of approximately HKD 1.2 billion for the first half, representing an increase year-on-year [3] - Hua Hong Semiconductor reported sales revenue of $635 million for Q3 2025, a year-on-year increase of 20.7%. However, net profit decreased by 42.6% to $25.725 million [4] - Autohome's net profit attributable to the parent company for Q3 was approximately RMB 436.6 million, with online marketing and other business revenues increasing by 32.1% year-on-year [5] - Xinyi International reported a cumulative net operating income of approximately HKD 13.981 billion for the first ten months, a year-on-year decrease of about 5.3%, with October revenue at HKD 1.457 billion [6] - Dongfeng Motor Group's cumulative vehicle sales for the first ten months reached 1.501 million units, a year-on-year decline of approximately 1.6%. However, sales of new energy vehicles increased by approximately 37.1% to 421,400 units [7] - China Overseas Land & Investment reported a cumulative contracted property sales amount of approximately RMB 189.165 billion for the first ten months, a year-on-year decrease of 21.3% [8] - Poly Property Group reported a cumulative contracted sales amount of RMB 43.8 billion for the first ten months, a year-on-year decrease of 10.43% [9] - Gemdale reported a cumulative contracted sales amount of approximately RMB 9.125 billion for the first ten months, a year-on-year decrease of 43.93% [10] - Sunac China reported a cumulative contract sales amount of approximately RMB 32.77 billion for the first ten months, a year-on-year decline of 25.1% [11] - Guoyin Financial Leasing plans to purchase 1,198 units of domestic information technology computing equipment for a total consideration of RMB 1.04 billion [12] - Youjia Innovation recently received project designation notifications from a globally renowned automotive group's joint venture and luxury brand, with a total order amount of approximately RMB 320 million [13] - Swire Properties reported a rental rate of 96% for Taikoo Place in Q3, with a rental reduction of 13%. Other Swire properties had an occupancy rate of 90%, with a rental reduction of 15% [14] - Zhongshen Construction Industry plans to acquire 100% equity of Huajian Development Co., Ltd. for approximately HKD 213.6 million [15] - Hard Egg Innovation signed a memorandum of understanding with Huixin Investment to jointly develop an AIoT innovation enterprise incubation platform [16] - Damai Entertainment expects mid-term net profit to increase to no less than RMB 500 million, compared to RMB 337 million last year [17] - Cafe de Coral Group issued a profit warning, expecting mid-term profit attributable to shareholders to decline by 65% to 70% [18] - Qingci Games signed a game licensing transfer agreement with Disney, obtaining authorization to develop and publish the game "Disney: Book of Legends," expected to launch in 2026 across various regions [19] - Now Medical Technology's subsidiary signed a strategic cooperation framework agreement with Medtronic Changzhou to promote clinical applications of real-time navigation tracking endoscopic technology in China [19] - Zhaoke Ophthalmology-B signed a distribution agreement with PT FERRON for the commercialization of BRIMOCHOL PF in Indonesia, receiving an upfront payment and potential milestone payments [19] - Shoujia Technology signed a strategic framework cooperation agreement with Stardust Intelligence, covering the development of humanoid robot tendon and related fields [20] Buyback Dynamics - Helen's decided to exercise its share buyback authorization, planning to repurchase up to 127 million shares [21] - China Feihe repurchased 6.806 million shares for a total of approximately HKD 29.4298 million, with a buyback price of HKD 4.29 to HKD 4.35 [22] - Kintor Pharmaceutical repurchased 1.734 million shares for a total of approximately HKD 26.3078 million, with a buyback price of HKD 14.35 to HKD 15.8 [23] - COSCO Shipping Holdings repurchased 1.53 million shares for a total of approximately HKD 20.9869 million, with a buyback price of HKD 13.57 to HKD 13.84 [24] - Sinopec repurchased 2.398 million H-shares for a total of approximately HKD 10.1066 million, with a buyback price of HKD 4.20 to HKD 4.23 [25]

Core Insights - Company Jin Hai Medical Technology (02225) has announced a strategic cooperation framework agreement with Medtronic's indirect wholly-owned subsidiary, Medtronic Changzhou Medical Devices Co., Ltd. [1] Group 1: Strategic Cooperation Details - The agreement aims to develop a leading domestic and internationally advanced integrated solution for real-time navigation tracking spinal endoscopy based on clinical needs [1] - The parties will invest resources to organize domestic and international academic exchange activities to promote clinical academic exchange and technological advancement of real-time navigation tracking spinal endoscopy technology in China [1] - They will mutually provide spinal endoscopy prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of real-time navigation tracking spinal endoscopy technology [1]

Core Viewpoint - The company has entered into a strategic cooperation framework agreement with Medtronic to promote real-time navigation tracking endoscopic technology for spinal applications in China [1] Group 1: Strategic Cooperation - The agreement involves the development of a leading domestic and internationally advanced integrated solution for navigation spinal endoscopy based on clinical needs [1] - Resources will be allocated to organize academic exchange activities domestically and internationally to promote clinical academic exchange and technological advancement of the real-time navigation tracking endoscopic technology in China [1] - Both parties will provide navigation spinal endoscopy prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the real-time navigation tracking endoscopic technology [1]

Core Viewpoint - The strategic cooperation framework agreement between Jinhai Medical Technology and Medtronic aims to promote the clinical application of real-time navigation tracking spinal endoscopy technology in China [1] Group 1: Strategic Cooperation Details - The agreement involves the development of a leading domestic and internationally advanced integrated solution for navigation spinal endoscopy based on clinical needs [1] - Resources will be allocated to organize domestic and international academic exchange activities to enhance clinical academic communication and technological advancement of the real-time navigation tracking spinal endoscopy technology in China [1] - Both parties will provide navigation spinal endoscopy prototypes for clinical demonstrations, training, and marketing activities to support the testing and evaluation of the technology [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 （股份代號：2225） （於開曼群島註冊成立的成員有限責任公司） 自願公告 戰略合作框架協議 茲提述今海醫療科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」） 日期為二零二五年十月十五日之自願公告（「十月自願公告」）。本公告乃由本公司 自願作出，旨在向其股東及潛在投資者提供有關本集團業務近期發展的最新情況。 除本公告另有界定者外，本公告所用詞彙與十月自願公告所界定者具有相同涵義。 有關美敦力常州的資料 美敦力常州為一間於中國成立之有限責任公司，主要從事醫療器械的製造及銷售。 美敦力常州為美敦力之間接全資附屬公司。 據董事經作出一切合理查詢後所知、所悉及所信，美敦力常州及美敦力為獨立於 本公司及其關連人士（定義見聯交所證券上市規則）的獨立第三方。 本公司董事（「董事」）會（「董事會」）欣然宣佈，於二零二 ...

Core Viewpoint - The stock of Jiuhai Medical Technology (02225.HK) experienced a significant increase, rising over 15% during trading, and is currently up 5.04% at HKD 1.25, with a trading volume of HKD 12.1974 million [1] Group 1 - Jiuhai Medical Technology's stock price increased by over 15% during the trading session [1] - As of the latest update, the stock is up 5.04%, trading at HKD 1.25 [1] - The total trading volume reached HKD 12.1974 million [1]

Core Viewpoint - Jin Hai Medical Technology (02225) has seen a significant stock price increase, attributed to its collaboration with Medtronic China to launch innovative navigation technology for spinal endoscopy during the 8th China International Import Expo [1] Company Summary - Jin Hai Medical Technology's stock rose over 15% during trading, currently up 5.04% at HKD 1.25, with a trading volume of HKD 12.1974 million [1] - The company announced a partnership with Medtronic China to unveil new navigation technology aimed at enhancing precision and intelligence in spinal surgeries [1] Industry Summary - The 8th China International Import Expo will take place from November 5 to 10 in Shanghai, providing a platform for showcasing innovative medical technologies [1] - Medtronic's core business includes the development, manufacturing, distribution, and sales of medical therapies and services across cardiovascular, neuroscience, surgical, and diabetes sectors [1] - Medtronic has participated in the Import Expo for seven consecutive years since its inception in 2018, leveraging the event's influence to accelerate the application of its latest medical innovations [1]